Atossa Therapeutics (ATOS) to Release Earnings on Monday

Atossa Therapeutics (NASDAQ:ATOS) is expected to post its quarterly earnings results before the market opens on Monday, April 7th. Analysts expect Atossa Therapeutics to post earnings of ($0.06) per share for the quarter.

Atossa Therapeutics (NASDAQ:ATOS) last announced its quarterly earnings data on Tuesday, March 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. On average, analysts expect Atossa Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Atossa Therapeutics Price Performance

Shares of ATOS stock opened at $0.60 on Friday. Atossa Therapeutics has a 1-year low of $0.60 and a 1-year high of $2.31. The stock has a market capitalization of $77.64 million, a PE ratio of -2.73 and a beta of 1.20. The business has a 50-day moving average of $0.76 and a 200 day moving average of $1.07.

Institutional Trading of Atossa Therapeutics

A hedge fund recently raised its stake in Atossa Therapeutics stock. Bank of America Corp DE boosted its holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 51.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 111,475 shares of the company’s stock after acquiring an additional 37,809 shares during the quarter. Bank of America Corp DE owned 0.09% of Atossa Therapeutics worth $105,000 at the end of the most recent quarter. Institutional investors and hedge funds own 12.74% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on ATOS shares. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Atossa Therapeutics in a report on Wednesday, March 26th. Ascendiant Capital Markets upped their target price on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a report on Monday, December 9th.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.